TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18028060

Group type: EXPERIMENTAL
Intervention: Phosphoric acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-etching primer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fuji IX GP (glass ionomer cement)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single Bond 2 (resin-based adhesive)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (resin-based adhesive)
Number of subjects: 0
Study: 16197283

Group type: EXPERIMENTAL
Intervention: Fast ForWord (FFW) intervention, home-based therapy for 6 weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Commercially available computer-based activities (control for computer games exposure)
Number of subjects: 77

Group type: COMPARATOR
Intervention: No additional study intervention
Number of subjects: 77
Study: 11834877

Group type: EXPERIMENTAL
Intervention: Dilazep dihydrochloride (300 mg/day, n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 60
Study: 10051861

Group type: EXPERIMENTAL
Intervention: Heel strike slips
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Midstance slips
Number of subjects: 65

Group type: COMPARATOR
Intervention: Older adults' responses to heel strike slips
Number of subjects: 65
Study: 7729995

Group type: EXPERIMENTAL
Intervention: Type B tympanogram
Number of subjects: 4214
Study: 1718721

Group type: EXPERIMENTAL
Intervention: Predictable rotation amplitude (serial 4 degrees versus serial 10 degrees)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unpredictable rotation amplitude (random mixture of 4 degrees and 10 degrees)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal subjects exposed to 2 perturbation amplitudes
Number of subjects: 0
Study: 7258754

Group type: EXPERIMENTAL
Intervention: Bretylium tosylate (10 mg/kg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 59
Study: 30895912

Group type: EXPERIMENTAL
Intervention: Randomized visual patterns (10% increments of checkerboard and randomized line orientation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ordered visual patterns (structured checkerboard and square array of vertical line segments)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preference results for openness and neuroticism
Number of subjects: 0
Study: 29996841

Group type: EXPERIMENTAL
Intervention: Absorbable tacks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-absorbable tacks
Number of subjects: 0
Study: 26786042

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg three times daily for 3 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 30
Study: 24760356

Group type: EXPERIMENTAL
Intervention: Psychoeducational group‐based HIV and STI prevention intervention
Number of subjects: 40
Study: 21542121

Group type: EXPERIMENTAL
Intervention: Continuing DAPT at 30 days (n = 4249)
Number of subjects: 4259

Group type: EXPERIMENTAL
Intervention: Continuing DAPT at 6 months (n = 2654)
Number of subjects: 4259

Group type: EXPERIMENTAL
Intervention: Continuing DAPT
Number of subjects: 4259
Study: 21136333

Group type: EXPERIMENTAL
Intervention: 5-day glucocorticoid treatment followed by 9 days of placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: 14-day course of systemic glucocorticoids (40 mg of prednisone-equivalent daily)
Number of subjects: 0
Study: 17645428

Group type: EXPERIMENTAL
Intervention: Prize-based contingency management (CM)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 388
Study: 14706762

Group type: EXPERIMENTAL
Intervention: Soy protein containing 99 mg naturally occurring isoflavones
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo (milk protein)
Number of subjects: 202
Study: 11871584

Group type: EXPERIMENTAL
Intervention: Assured Treatment (AT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Disbeliever Treatment (DT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-Targeted Treatment (NT)
Number of subjects: 59
Study: 9926278

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 2‐8 mg/day orally for 8‐12 weeks
Number of subjects: 10
Study: 7819982

Group type: EXPERIMENTAL
Intervention: DICE therapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Red dice therapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Excluding red dice trials and poor methodological quality trials
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Published trials
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Trials with familiar trialists
Number of subjects: 44
Study: 3061859

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 78

Group type: COMPARATOR
Intervention: 800 mg cimetidine
Number of subjects: 78
Study: 31174454

Group type: EXPERIMENTAL
Intervention: Process and outcome feedback
Number of subjects: 197

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 197
Study: 29447778

Group type: EXPERIMENTAL
Intervention: 80 mg/day atorvastatin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 28070889

Group type: EXPERIMENTAL
Intervention: Guided parent-delivered cognitive behaviour therapy (CBT)
Number of subjects: 57
Study: 26047719

Group type: EXPERIMENTAL
Intervention: Parent presence during speech preparation (N=39)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Stranger presence during speech preparation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Parent presence during speech preparation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cortisol reactivity to the TSST-M
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Salivary alpha-amylase levels
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Subjective stress ratings for the task
Number of subjects: 75
Study: 23115341

Group type: EXPERIMENTAL
Intervention: No change condition (yellow tablet 'Betaprol')
Number of subjects: 62

Group type: COMPARATOR
Intervention: Generic change condition (white tablet 'Generic')
Number of subjects: 62

Group type: COMPARATOR
Intervention: Branded change condition (white tablet 'Novaprol')
Number of subjects: 62
Study: 21147420

Group type: EXPERIMENTAL
Intervention: Indirect tri-planar MFR technique (3 min)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Hot pack application (20 min)
Number of subjects: 31
Study: 19072483

Group type: EXPERIMENTAL
Intervention: XIENCE V Everolimus-Eluting Coronary Stent System
Number of subjects: 2000

Group type: COMPARATOR
Intervention: CYPHER Plus
Number of subjects: 2000
Study: 15611456

Group type: EXPERIMENTAL
Intervention: Nasojejunal tube placement (NJT group)
Number of subjects: 237

Group type: COMPARATOR
Intervention: No nasojejunal tube placement (no-NJT group)
Number of subjects: 237
Study: 10422616

Group type: EXPERIMENTAL
Intervention: Light-intensity exercise
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 80
Study: 7488565

Group type: EXPERIMENTAL
Intervention: Scaffolded instruction
Number of subjects: 41

Group type: COMPARATOR
Intervention: Didactic instruction
Number of subjects: 41
Study: 2272819

Group type: EXPERIMENTAL
Intervention: Self-help relaxation training
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chlormezanone (muscle relaxant)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Waiting-list group
Number of subjects: 48
Study: 540525

Group type: EXPERIMENTAL
Intervention: Piracetam (2.4 g per day)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 31125823

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20 mg tid for 14 days
Number of subjects: 39
Study: 27506309

Group type: EXPERIMENTAL
Intervention: 2 hours of poikilocapnic normobaric hypoxia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 hours of poikilocapnic normobaric hypoxia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypercapnic challenge (5% CO2)
Number of subjects: 0
Study: 26948962

Group type: EXPERIMENTAL
Intervention: aerobic dance
Number of subjects: 120
Study: 25390870

Group type: EXPERIMENTAL
Intervention: Immediate loading protocol (G1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Early loading protocol (G2)
Number of subjects: 36
Study: 22559251

Group type: EXPERIMENTAL
Intervention: Low-intensity information program (Spanish-language video)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: High-intensity program (video + 'promotora' intervention)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control arm (usual care)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Patient navigator program
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness evaluation of intervention programs
Number of subjects: 600
Study: 20073212

Group type: EXPERIMENTAL
Intervention: Compound salvia injection (20 mL in 10% glucose 500 mL for intravenous dripping once a day) and UDCA (15 mg, thrice daily by oral taken)
Number of subjects: 128

Group type: COMPARATOR
Intervention: UDCA alone
Number of subjects: 128
Study: 17526181

Group type: EXPERIMENTAL
Intervention: Scalp-acupuncture drawing method (SADM)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Scalp-acupuncture twirling method (SATM)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No additional treatment (Control group II)
Number of subjects: 93
Study: 15259516

Group type: EXPERIMENTAL
Intervention: Fentanyl (1 microg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Meperidine (1 mg/kg)
Number of subjects: 24
Study: 11211004

Group type: EXPERIMENTAL
Intervention: Student-controlled multiple views
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: High spatial ability of the student
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Self-directed examination of an object from multiple different perspectives
Number of subjects: 146
Study: 9526894

Group type: EXPERIMENTAL
Intervention: Fat-rich diet (T-FAT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Carbohydrate-rich diet (T-CHO)
Number of subjects: 15
Study: 8018611

Group type: EXPERIMENTAL
Intervention: Ampicillin and metronidazole for five days
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 81
Study: 2591060

Group type: EXPERIMENTAL
Intervention: Octreotide (250 micrograms/day in 4 divided s.c. injections for 1 month, followed by continuous s.c. infusions for another month, then 200 micrograms three times daily as s.c. injections)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Octreotide treatment
Number of subjects: 9
Study: 31833226

Group type: EXPERIMENTAL
Intervention: Metformin treatment (1 day and 4 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metformin treatment (4 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 10
Study: 28291237

Group type: EXPERIMENTAL
Intervention: 4-L split-dose polyethylene-glycol (PEG) regimen
Number of subjects: 256

Group type: COMPARATOR
Intervention: 2-L split-dose PEG plus ascorbic acid (PEG+Asc) regimen
Number of subjects: 256
Study: 25881037

Group type: EXPERIMENTAL
Intervention: Samata intervention
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2100
Study: 22951028

Group type: EXPERIMENTAL
Intervention: Water exercise training program that includes perturbation exercises (WEP) for 12 weeks.
Number of subjects: 36

Group type: COMPARATOR
Intervention: No intervention for the first 12 weeks (Control Group B).
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Water exercise training program that includes perturbation exercises (WEP) for 12 weeks (Control Group B).
Number of subjects: 36
Study: 21866432

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1 mg·kg(‐1) iv
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 2 mg·kg(‐1) iv
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (Control group)
Number of subjects: 120
Study: 19897689

Group type: EXPERIMENTAL
Intervention: Management based on symptoms
Number of subjects: 46

Group type: COMPARATOR
Intervention: Speculum examination and wet mount (Control)
Number of subjects: 46
Study: 17518165

Group type: EXPERIMENTAL
Intervention: Victorian ANF nurse members
Number of subjects: 574
Study: 15358014

Group type: EXPERIMENTAL
Intervention: Intracoronary brachytherapy (ICB)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No radiation (Control)
Number of subjects: 92
Study: 11777191

Group type: EXPERIMENTAL
Intervention: Megestrol acetate liquid suspension 800 mg/day
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Dronabinol tablets 2.5 mg b.i.d.
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Combination of megestrol acetate and dronabinol
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Alterations in appetite (reported by patients)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Changes in serum IL-6
Number of subjects: 85
Study: 9834804

Group type: EXPERIMENTAL
Intervention: Desflurane/N2O (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Desflurane alone (Group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 8027215

Group type: EXPERIMENTAL
Intervention: Octreotide (4 months treatment)
Number of subjects: 86
Study: 2917597

Group type: EXPERIMENTAL
Intervention: Viqualine 75 mg bd
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ethanol (blood alcohol concentrations of 17-22 mmol.l-1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Viqualine
Number of subjects: 16
Study: 4149613

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prindolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol and other beta-blockers
Number of subjects: 0
Study: 30683074

Group type: EXPERIMENTAL
Intervention: Resting state functional connectivity analysis in adults with ADHD
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Age-related analysis
Number of subjects: 38
Study: 28057361

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg (weeks 0 and 4, then every 8 weeks)
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: guselkumab maintenance
Number of subjects: 992

Group type: COMPARATOR
Intervention: adalimumab (80 mg week 0, then 40 mg week 1, and every 2 weeks through week 23)
Number of subjects: 992

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 992

Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 992
Study: 25325371

Group type: EXPERIMENTAL
Intervention: Head of Bed (HOB) elevation to 15°
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard care with HOB completely flat
Number of subjects: 71
Study: 23356246

Group type: EXPERIMENTAL
Intervention: Goal-focused lifestyle coaching delivered by telephone over a one-year period
Number of subjects: 2840

Group type: COMPARATOR
Intervention: Control arm (no specific intervention mentioned)
Number of subjects: 2840
Study: 21526412

Group type: EXPERIMENTAL
Intervention: Adherence behaviour measures (intentional nonadherence associated with self-regulation)
Number of subjects: 1426

Group type: EXPERIMENTAL
Intervention: Adherence behaviour measures (intentional nonadherence associated with effect concerns)
Number of subjects: 1426

Group type: EXPERIMENTAL
Intervention: Adherence behaviour measures (non-intentional non-adherence)
Number of subjects: 1426

Group type: EXPERIMENTAL
Intervention: Established measures of non-adherence
Number of subjects: 1426

Group type: EXPERIMENTAL
Intervention: Self-efficacy measures
Number of subjects: 1426
Study: 18266550

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 32
Study: 16505284

Group type: EXPERIMENTAL
Intervention: Prognostic Inflammatory and Nutritional Index (PINI) assessment based on albumin, alpha1‐acid glycoprotein, C‐reactive protein, and prealbumin measurements.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PINI assessment
Number of subjects: 0
Study: 15253125

Group type: COMPARATOR
Intervention: Healthy group (N=25)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: HIE group (N=16)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 11403980

Group type: EXPERIMENTAL
Intervention: 50 mg DHEA daily for 13 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo for 13 weeks
Number of subjects: 46
Study: 9409946

Group type: EXPERIMENTAL
Intervention: Quinolones (ciprofloxacin, 500 mg/12 h per os; pefloxacin, 200 mg/12 h intravenous)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Tetracyclines (rolitetracycline, 275 mg/12 h intravenous)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 39
Study: 8323891

Group type: COMPARATOR
Intervention: Epidural fentanyl (1.0 mcg.kg‐1) followed by continuous infusion of fentanyl (1.0 mcg.kg‐1h‐1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (1.0 mcg.kg‐1) followed by continuous infusion of fentanyl (0.5 mcg.kg‐1 x h‐1) and clonidine (0.3 mcg.kg‐1 x h‐1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl + clonidine
Number of subjects: 25
Study: 3095503

Group type: COMPARATOR
Intervention: Cisplatin with 3% saline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cisplatin with mannitol diuresis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Triple-drug combination of methotrexate (MTX), 5-fluorouracil (5-FU), and cisplatin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 50
Study: 29298124

Group type: EXPERIMENTAL
Intervention: Budesonide 200 μg twice/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Budesonide 800 μg twice/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 27664217

Group type: EXPERIMENTAL
Intervention: Immediate insertion of etonogestrel releasing implant (inserted 1 hour after mifepristone intake)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Routine insertion of etonogestrel releasing implant (inserted at follow-up 2-4 weeks later)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Immediate insertion of etonogestrel releasing implant
Number of subjects: 551

Group type: COMPARATOR
Intervention: Routine insertion of etonogestrel releasing implant
Number of subjects: 551
Study: 23995299

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0
Study: 22935338

Group type: EXPERIMENTAL
Intervention: Quercetin (Q) 1095 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study: 20863929

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (S75-R25)
Number of subjects: 49

Group type: COMPARATOR
Intervention: 0.20% ropivacaine
Number of subjects: 49
Study: 19011774

Group type: EXPERIMENTAL
Intervention: 1.2 ml (6 mg) of 0.5% hyperbaric bupivacaine with 0.16 mg of morphine (group BM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1.2 ml (6 mg) of 0.5% hyperbaric bupivacaine (group B)
Number of subjects: 60
Study: 16164158

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg once daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 70
Study: 14503673

Group type: EXPERIMENTAL
Intervention: Pilots
Number of subjects: 19

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 19
Study: 10984265

Group type: EXPERIMENTAL
Intervention: octreotide LAR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lanreotide
Number of subjects: 0

Group type: COMPARATOR
Intervention: subcutaneous octreotide
Number of subjects: 0
Study: 9538650

Group type: EXPERIMENTAL
Intervention: Atrial signal-averaged electrocardiogram (ASAECG) parameters
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Criteria for identification of PAF
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (patients without PAF)
Number of subjects: 53
Study: 8251842

Group type: EXPERIMENTAL
Intervention: Oxytocin-ergometrine
Number of subjects: 3497

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 3497
Study: 3099490

Group type: EXPERIMENTAL
Intervention: Transdermally applied nitroglycerin (TDS) 5.0 mg in 24 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sustained release nitroglycerin capsules (NTR) 2.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transdermally applied nitroglycerin (TDS) after 3 months
Number of subjects: 12
Study: 29301785

Group type: EXPERIMENTAL
Intervention: Baseline Lp(a) levels
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: On-study Lp(a) levels
Number of subjects: 152

Group type: COMPARATOR
Intervention: Intensive lipid therapy (LDL-C <70 mg/dL)
Number of subjects: 152
Study: 26921488

Group type: EXPERIMENTAL
Intervention: Baseline concentrations of unacylated ghrelin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline total ghrelin in females
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leptin:ghrelin ratio in females
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline concentrations of leptin, adiponectin, and ghrelin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ratio of acylated:unacylated ghrelin
Number of subjects: 0
Study: 24593225

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) 100 cc, 0.7 mM polyphenols, three times a week for one year
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 101
Study: 21751770

Group type: EXPERIMENTAL
Intervention: Sign Chi Do (SCD) exercise intervention for 12 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Minimal education control group
Number of subjects: 67
Study: 20216073

Group type: EXPERIMENTAL
Intervention: Family Healthware intervention (web-based tool for recording family medical history)
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Family Healthware intervention
Number of subjects: 2330

Group type: COMPARATOR
Intervention: Baseline perceptions (before Family Healthware intervention)
Number of subjects: 2330
Study: 18925346

Group type: EXPERIMENTAL
Intervention: Placebo + medical management
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Specialized behavioral therapy + placebo + medical management
Number of subjects: 466

Group type: COMPARATOR
Intervention: Specialized behavioral therapy alone
Number of subjects: 466